Century Therapeutics, Inc. Lease, Cost
Century Therapeutics, Inc. (IPSC) reported Lease, Cost of $2.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-12
- Century Therapeutics, Inc. lease, cost for the quarter ending 2026-06-30 was $2.43M, a 1.22% decline year-over-year.
- Century Therapeutics, Inc. lease, cost for the quarter ending 2026-03-31 was $2.75M, a 14.16% increase year-over-year.
- Century Therapeutics, Inc. lease, cost for the quarter ending 2025-12-31 was $2.70M, a 10.52% increase year-over-year.
- Century Therapeutics, Inc. lease, cost for the quarter ending 2025-09-30 was $1.90M, a 18.06% decline year-over-year.
- Century Therapeutics, Inc. lease, cost for fiscal 2025 was $9.47M, a 0.85% increase from fiscal 2024.
- Century Therapeutics, Inc. lease, cost for fiscal 2024 was $9.39M, a 16.43% increase from fiscal 2023.
- Century Therapeutics, Inc. lease, cost for fiscal 2023 was $8.06M, a 6.93% decline from fiscal 2022.
- Century Therapeutics, Inc. lease, cost for fiscal 2022 was $8.66M, a 54.91% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.43M 10-Q · filed 2026-08-12 | $5.18M 10-Q · filed 2026-08-12 | $7.88M derived: sum of 3 quarters · filed 2026-08-12 | $9.78M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.75M 10-Q · filed 2026-05-13 | $5.45M derived: sum of 2 quarters · filed 2026-05-13 | $7.35M derived: sum of 3 quarters · filed 2026-05-13 | $9.81M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.60M derived: sum of 2 quarters · filed 2026-03-12 | $7.06M derived: sum of 3 quarters · filed 2026-08-12 | $9.47M 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.90M 10-Q · filed 2025-11-13 | $4.36M derived: sum of 2 quarters · filed 2026-08-12 | $6.77M 10-Q · filed 2025-11-13 | $9.21M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $2.46M 10-Q · filed 2026-08-12 | $4.87M 10-Q · filed 2026-08-12 | $7.31M derived: sum of 3 quarters · filed 2026-08-12 | $9.63M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.41M 10-Q · filed 2026-05-13 | $4.85M derived: sum of 2 quarters · filed 2026-05-13 | $7.17M derived: sum of 3 quarters · filed 2026-05-13 | $10.26M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.76M derived: sum of 2 quarters · filed 2026-03-12 | $7.85M derived: sum of 3 quarters · filed 2026-03-12 | $9.39M 10-K · filed 2026-03-12 |
| 2024-09-30 | $2.32M 10-Q · filed 2025-11-13 | $5.41M derived: sum of 2 quarters · filed 2025-11-13 | $6.95M 10-Q · filed 2025-11-13 | $8.66M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $3.09M 10-Q · filed 2025-08-14 | $4.63M 10-Q · filed 2025-08-14 | $6.34M derived: sum of 3 quarters · filed 2025-08-14 | $8.26M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.53M 10-Q · filed 2025-05-15 | $3.25M derived: sum of 2 quarters · filed 2025-05-15 | $5.17M derived: sum of 3 quarters · filed 2025-05-15 | $7.49M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $3.63M derived: sum of 2 quarters · filed 2025-03-19 | $5.95M derived: sum of 3 quarters · filed 2025-03-19 | $8.06M 10-K · filed 2025-03-19 |
| 2023-09-30 | $1.92M 10-Q · filed 2024-11-05 | $4.24M derived: sum of 2 quarters · filed 2024-11-05 | $6.35M 10-Q · filed 2024-11-05 | $8.91M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $2.32M 10-Q · filed 2024-08-08 | $4.43M 10-Q · filed 2024-08-08 | $6.99M derived: sum of 3 quarters · filed 2024-08-08 | $9.69M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.11M 10-Q · filed 2024-05-09 | $4.67M derived: sum of 2 quarters · filed 2024-05-09 | $7.37M derived: sum of 3 quarters · filed 2024-05-09 | $9.24M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $5.25M derived: sum of 2 quarters · filed 2024-03-14 | $7.12M derived: sum of 3 quarters · filed 2024-03-14 | $8.66M 10-K · filed 2024-03-14 |
| 2022-09-30 | $2.70M 10-Q · filed 2023-11-09 | $4.57M derived: sum of 2 quarters · filed 2023-11-09 | $6.11M 10-Q · filed 2023-11-09 | $7.52M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.87M 10-Q · filed 2023-08-09 | $3.41M 10-Q · filed 2023-08-09 | $4.82M derived: sum of 3 quarters · filed 2023-08-09 | $6.19M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $1.54M 10-Q · filed 2023-05-11 | $2.96M derived: sum of 2 quarters · filed 2023-05-11 | $4.33M derived: sum of 3 quarters · filed 2023-05-11 | $5.65M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $2.78M derived: sum of 2 quarters · filed 2023-03-16 | $4.11M derived: sum of 3 quarters · filed 2023-03-16 | $5.59M 10-K · filed 2023-03-16 |
| 2021-09-30 | $1.37M 10-Q · filed 2022-11-10 | $2.69M derived: sum of 2 quarters · filed 2022-11-10 | $4.18M 10-Q · filed 2022-11-10 | $5.25M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.32M 10-Q · filed 2022-08-11 | $2.81M 10-Q · filed 2022-08-11 | $3.88M derived: sum of 3 quarters · filed 2022-08-11 | $4.84M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $1.49M 10-Q · filed 2022-05-16 | $2.56M derived: sum of 2 quarters · filed 2022-05-16 | $3.52M derived: sum of 3 quarters · filed 2022-05-16 | $4.28M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $2.03M derived: sum of 2 quarters · filed 2022-03-17 | $2.80M derived: sum of 3 quarters · filed 2022-03-17 | $3.42M 10-K · filed 2022-03-17 |
| 2020-09-30 | $959.00K 10-Q · filed 2021-11-10 | $1.72M derived: sum of 2 quarters · filed 2021-11-10 | $2.35M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $765.00K 10-Q · filed 2021-08-12 | $1.39M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |